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requent Detection of
amilial Hypercholesterolemia
utations in Familial
ombined Hyperlipidemia*
ail P. Jarvik, MD, PHD,†§ John D. Brunzell, MD,‡
rno G. Motulsky, MD, SCD†§
eattle, Washington
amilial combined hyperlipidemia (FCH) is the most com-
on genetic cause of hyperlipidemia, affecting approxi-
ately 1% of the population. It was first described in the
eattle Myocardial Infarction Study in 1973 (1). This
ondition is characterized by variable lipid phenotypes
increased levels of triglycerides or cholesterol or both lipids)
n the proband and in relatives that may vary within an
ndividual person from time to time. Familial combined
yperlipidemia contributes to 20% of coronary artery
isease in males under the age of 60 years (2,3).
See page 1546
The diagnosis of FCH is difficult, requiring data from
amily members who may not be available. Percentile
utoffs, often 90th or 95th percentile for cholesterol,
ow-density lipoprotein (LDL)-cholesterol, or triglyceride
levations, are utilized to establish the diagnosis. As lipid
evels vary over time, both a negative and a positive
iagnosis can be unreliable. An increase in apolipoprotein B
apoB) (4,5), together with elevated numbers of small, dense
DL particles, appears to be a more consistent phenotype
or FCH than are total cholesterol and triglycerides, whose
evels vary over time (6).
Although originally described as autosomal dominant, more
ecent data indicate a more complex inheritance. Several loci
ith major and minor impacts on risk of FCH, as well as
nvironmental factors, have been demonstrated.
Variants in upstream transcription factor (USF)-1 were
inked in a Finnish FCH cohort (7) and associated in Dutch
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine (†Division of Medical Genetics and ‡Divisionl
f Metabolism, Endocrinology, and Nutrition) and the §Department of Genome
ciences, University of Washington Medical Center, Seattle, Washington.atients (8) and Mexican patients (9). Paradoxically, a dyslip-
demia haplotype was associated with lower cardiovascular
isease risk (10). The USF-1 dyslipidemia haplotype has been
ssociated with lower interleukin-6 and C-reactive protein
evels increasing with age, suggesting that the reduced risk may
ot involve regulation of lipid genes (11).
However, this locus only accounts for some FCH fami-
ies, suggesting other factors remain undetected. Other loci
mplicated include lipoprotein lipase (12) and the apoli-
oprotein A1/C3/A4/A5 gene cluster (13,14). Additionally,
large number of chromosomal regions have been impli-
ated by linkage in FCH families. Clearly, FCH is geneti-
ally heterogeneous.
Heterozygous familial hypercholesterolemia (FH) is di-
gnosed based on high LDL-cholesterol levels (usually
250 mg/dl) in untreated adults and frequent tendinous
anthomas. Familial hypercholesterolemia, which is autoso-
al dominant and associated with early vascular disease, can
e confirmed by molecular demonstration of a mutant LDL
eceptor (LDLR) gene. However, molecular studies are
arely done clinically, as the results do not influence treat-
ent. A defect in the ligand for the LDLR, apoB, is a less
ommon cause of FH, as are missense mutations of PCSK9
15). FH occurs in about 1 in 500 persons in the population,
nd accounts for approximately 4% of premature myocardial
nfarctions (1). Hypertriglyceridemia can independently oc-
ur in FH, causing mixed hyperlipidemia and leading to
onfusion with FCH.
Against this background and potential uncertainties
bout the diagnosis of FCH, Civiera et al. (16) searched for
lassical FH mutations in FCH using probes for 203 LDLR
utations and 4 apoB mutations. Their novel microarray
echniques (Lipochip) (17) recognized 88% of 230 different
DLR mutations from Spain. Methodology to find rear-
angements in the LDLR gene was also utilized (18). In all,
43 unrelated middle-aged men and women with FCH
ere selected from the clinical records of 2 lipid clinics (16).
nclusion required LDL-cholesterol levels of 170 mg/dl
r non–high-density lipoprotein-cholesterol of220 mg/dl
hen triglyceride levels were over 400 mg/dl. At least 1
rst-degree relative had to have hyperlipidemia, which was
efined as total cholesterol and/or triglyceride levels 90th
ercentile. Functional LDLR mutations were found in 28
atients (20%). No apoB mutations were detected. Patients
ith LDLR mutations had higher levels of cholesterol
DL-cholesterol and apoB levels as compared with patients
ithout these mutations, and their triglyceride levels were
omewhat higher than in patients without LDLR muta-
ions. Diabetes mellitus was found in 26 patients (23%)
ithout LDLR mutations and was absent in all LDLR
utation carriers. Considering only nondiabetic patients
ith cholesterol levels of 335 mg/dl and apoB levels of
185 mg/dl, 48 patients (or 42% of study subjects) had
DLR mutations. The detected LDLR mutations wereikely to be pathogenic, as most of the LDLR abnormalities
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November 4, 2008:1554–6 FH Mutations in FCHn this study had been observed in other Spanish FH
atients (17).
Although it is not surprising that “weaker” mutations in
DLR might result in diagnostic uncertainty in the absence
f molecular diagnosis, the high frequency of FH mutations
n nondiabetic patients with a presumptive clinical diagnosis
f FCH is unexpected. Whereas part of this excess can be
scribed to selection or referral bias of more complicated
atients to a referral center, and to the atypically high LDL
evels in this cohort, these data indicate potential difficulties
ith the clinical diagnoses of FH and FCH. Subjects with
DLR mutations lacked tendon xanthomas, which would
ave suggested FH but frequently are absent. Furthermore,
atients with LDLR mutations in this study had lower lipid
evels than those typical for FH. The lack of persons with
solated elevated triglyceride levels in a family with pre-
umptive FCH should suggest the possibility of FH rather
han FCH.
Similar studies on FCH using molecular search for
DLR mutations are strongly suggested. What should be
he role of molecular testing for LDLR mutations in FCH?
urrently, LDLR molecular studies are rarely done clini-
ally, owing to the absence of both the impact on patient
anagement and the ability to test for affected relatives
sing lipid determination rather than molecular studies,
hich are not generally available. Although the presence of
LDLR mutation allows definite diagnosis of FH, studies
f lipid levels alone will give informative diagnostic results
n affected and nonaffected family members in both FH and
CH.
Should molecular testing be more widely utilized, some
onsideration must be given to the optimal test. Available
ptions include coverage of the whole gene with current
equencing methodology (19) or a microarray including
ndividual known mutations such as used by the current
tudy (16) and the study by Tejedor et al. (17). The content
f a microarray mutation panel for FH detection must, of
ourse, reflect the various mutations in a given population,
hich varies. Note that at least 800 different FH mutations
xist. With the falling cost of comprehensive deoxyribonu-
leic acid sequencing, an approach covering the entire
DLR gene, including promoters, is likely to detect all
DLR mutations and ultimately will be possible.
A separate issue is the utility of APOE testing in subjects
ith a presumptive diagnosis of FCH. Again, it is useful to
onsider whether knowledge of the results of the diagnostic
est will change management of the patient. For APOE,
here are special considerations because the APOE 4 allele
s a risk factor for late-onset Alzheimer’s disease and is
ound in approximately 25% of heterozygotes in the popu-
ation (24 and 34) and in 1% of homozygotes (44)
20), depending on race. Testing for APOE, therefore,
equires a tailored approach. In the study under discussion
16), 4 of 115 FCH patients carried the APOE 22
enotype. These patients have type III hyperlipidemia
dysbetalipoproteinemia or remnant removal disease), whichan be diagnosed by examining very low-density lipoprotein
omposition (21) or with APOE phenotyping by gradient
el electrophoresis (21). Less than 1% of most populations
arry such APOE 22. In view of the higher risk of
lzheimer’s disease—2 to 3 times higher for 4 heterozy-
otes and 15 times higher for 44 homozygotes (22)
ompared with non-4 genotypes—and the fact that 2 and
4 are separately testable polymorphisms, many physicians
equest only APOE 2 testing or do not inform patients of
heir APOE 4 status and its predictive significance for
lzheimer’s disease. Ideally, before any testing that may
isclose 4 status, all patients should be advised about
otential risks for Alzheimer’s disease and offered clinical
enetics consultation.
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artment of Medicine, Division of Medical Genetics, University of
ashington Medical Center, Box 357720, Seattle, Washington
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